What happened, in summary

Janice Cowden was first diagnosed with breast cancer in 2011. Nearly 5 years later, she developed metastatic breast cancer and was told she had Stage IV disease. She was 33 when the diagnosis shattered her sense of the future. Biopsy was needed to confirm whether the cancer was still triple-negative, and the story later describes it as triple-negative breast cancer. Janice had chemotherapy both times because targeted therapies were not available for triple-negative disease at that point. Her earlier treatment included Taxotere-Cytoxan and was difficult enough that she needed 2 dose reductions. After the metastatic diagnosis, she received Adriamycin-Cytoxan, a regimen she described as harsh. Much of Janice’s story focuses on why the “right dose” matters. She developed severe mouth sores, systemic thrush, alternating diarrhea and constipation, runny eyes and nose, and lost about 18 pounds in 3 months because eating and drinking became painful. Dose reductions helped, but even reduced doses could be hard to tolerate. As of June 2026, Janice was living with incurable Stage IV triple-negative breast cancer and advocating for patients to talk openly with their oncology teams about side effects, dose adjustments, quality of life, and staying on treatment in a way the body can endure.